Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation.

@article{Cappato2014RivaroxabanVV,
  title={Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation.},
  author={Riccardo Cappato and Michael Ezekowitz and Allan L. Klein and A. John Camm and Chang-Sheng Ma and Jean-Yves le Heuzey and Mario R Talajic and Maur{\'i}cio Ibrahim Scanavacca and Panos E. Vardas and Paulus Kirchhof and Melanie Hemmrich and Vivian Lanius and Isabelle Ling Meng and Peter Wildgoose and Martin van Eickels and Stefan H. Hohnloser},
  journal={European heart journal},
  year={2014},
  volume={35 47},
  pages={3346-55}
}
AIMS X-VeRT is the first prospective randomized trial of a novel oral anticoagulant in patients with atrial fibrillation undergoing elective cardioversion. METHODS AND RESULTS We assigned 1504 patients to rivaroxaban (20 mg once daily, 15 mg if creatinine clearance was between 30 and 49 mL/min) or dose-adjusted vitamin K antagonists (VKAs) in a 2:1 ratio. Investigators selected either an early (target period of 1-5 days after randomization) or delayed (3-8 weeks) cardioversion strategy. The… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 49 times over the past 90 days. VIEW TWEETS
81 Citations
16 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 81 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 16 references

Similar Papers

Loading similar papers…